ClinicalTrials.gg

Program

teduglutide

Also written as “Teduglutide”, “Teduglutide 0.05 mg/kg/d” and “Teduglutide 0.1 mg/kg/d”.

Its studies are mostly in Short Bowel Syndrome · Crohn Disease · Renal Insufficiency, led by Takeda.

Furthest: phase 3, since Apr 13, 200424 company-led studies, 1 open or runningNext primary completion: Feb 10, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda241 open or runningphase 3since Apr 13, 2004Nov 11, 2003Feb 10, 2027phase 3 · NCT06973304

Also a collaborator on its studies: takeda-development-center-americas-inc, nycomed-germany-gmbh and nps-pharma.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Nov 11, 2003.

  1. Sep 20, 2010Phase 1 study in Healthy VolunteersNCT01209351 · 36 enrolled · United States
  2. Mar 13, 2012Phase 3 study in Short Bowel SyndromeNCT01560403 · 14 enrolled · United States
  3. Sep 23, 2013Phase 3 study in Short Bowel SyndromeNCT01952080 · 42 enrolled · United States, United Kingdom
  4. Nov 13, 2014Phase 3 study in Short Bowel SyndromeNCT02340819 · 11 enrolled · Japan
  5. Jan 27, 2016Phase 3 study in Short Bowel SyndromeNCT02682381 · 59 enrolled · United States, Belgium, Canada and more
  6. Oct 5, 2016Phase 3 study in Short Bowel SyndromeNCT02949362 · 29 enrolled · United States, United Kingdom
  7. Nov 30, 2016Phase 3 study in Short Bowel SyndromeNCT02980666 · 10 enrolled · Japan
  8. Aug 10, 2017Phase 3 study in Short Bowel SyndromeNCT03268811 · 9 enrolled · Japan
  9. May 3, 2018Phase 3 study in Short Bowel SyndromeNCT03571516 · 10 enrolled · Finland, France, Italy and more
  10. Jun 28, 2018Phase 3 study in Short Bowel SyndromeNCT03596164 · 11 enrolled · Japan
  11. Aug 28, 2018Phase 3 study in Short Bowel SyndromeNCT03663582 · 7 enrolled · Japan
  12. Jul 7, 2020Phase 1 study in Healthy VolunteersNCT04465396 · 64 enrolled · United States
  13. Aug 26, 2021Phase 3 study in Short Bowel SyndromeNCT05027308 · 3 enrolled · Japan
  14. May 8, 2025Phase 3 study in Short Bowel SyndromeNCT06973304 · 13 enrolled · China

Ahead

  1. Feb 10, 2027Primary completion: phase 3 study in Short Bowel SyndromeNCT06973304

TargetBeta

GLP2R →read by rule
“Glucagon-like peptide 2 receptor agonist”ChEMBL 37, by rule

Studies

All 24 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06973304Short Bowel Syndrome · China3Active, not recruitingFeb 10, 202713
NCT05027308Short Bowel Syndrome · Japan3CompletedSep 27, 20233
NCT04465396Healthy Volunteers · United States1CompletedAug 20, 202164
NCT03663582Short Bowel Syndrome · Japan3CompletedAug 6, 20197
NCT03596164Short Bowel Syndrome · Japan3CompletedJan 13, 202211
NCT03571516Short Bowel Syndrome · Finland, France, Italy and more3CompletedSep 24, 202010
NCT03268811Short Bowel Syndrome · Japan3CompletedNov 2, 20219
NCT02980666Short Bowel Syndrome · Japan3CompletedJan 21, 202010
NCT02949362Short Bowel Syndrome · United States, United Kingdom3CompletedJul 14, 202029
NCT02682381Short Bowel Syndrome · United States, Belgium, Canada and more3CompletedAug 18, 201759
NCT02340819Short Bowel Syndrome · Japan3CompletedNov 5, 201811
NCT01952080Short Bowel Syndrome · United States, United Kingdom3CompletedJan 9, 201542
NCT01560403Short Bowel Syndrome · United States3CompletedJul 23, 201314
NCT01209351Healthy Volunteers · United States1CompletedNov 8, 201036
NCT01028924Short Bowel Syndrome · Germany1CompletedFeb 201072
NCT01028768Renal Insufficiency · Germany1CompletedJan 201036
NCT00930644Short Bowel Syndrome · United States, Canada, Denmark and more3CompletedJan 24, 201388
NCT00820885Pharmacokinetics and Safety of Elevated Doses · United States1CompletedApr 23, 200795
NCT00819468Hepatic Impairment · United States1CompletedAug 23, 200724
NCT00798967Short Bowel Syndrome · United States, Canada, Denmark and more3CompletedJan 25, 201186
NCT00308438Crohn Disease · United States, Canada2CompletedNov 1, 200567
NCT00172185Short Bowel Syndrome · United States, Belgium, Canada and more3CompletedJan 24, 200865
NCT00081458Short Bowel Syndrome · United States, Belgium, Canada and more3CompletedJul 6, 200784
NCT00072839Crohn Disease · United States, Canada2CompletedJul 28, 2005100

How it is read

Names in the registry

  • “Teduglutide”, 14 entries
  • “teduglutide”, 6 entries
  • “Teduglutide 0.05 mg/kg/d”, 1 entry
  • “Teduglutide 0.1 mg/kg/d”, 1 entry
  • “Teduglutide 0.05mg/kg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.